Antineoplastic drugs inducing cardiac and vascular toxicity - An update
Vascul Pharmacol. 2023 Sep 7;153:107223. doi: 10.1016/j.vph.2023.107223. Online ahead of print.ABSTRACTWith the improvement in cancer prognosis due to advances in antitumor therapeutic protocols and new targeted and immunotherapies, we are witnessing a growing increase in survival, however, at the same timeincrease in morbidity among cancer survivors as a consequences of the increased cardiovascular adverse effects of antineoplastic drugs. Common cardiovascular complications of antineoplastic therapies may include cardiac complications such as arrhythmias, myocardial ischemia, left ventricular dysfunction culminating in he...
Source: Vascular Pharmacology - September 7, 2023 Category: Drugs & Pharmacology Authors: Serena Barachini Sandra Ghelardoni Zolt án V Varga Radwa A Mehanna Maria Magdalena Montt-Guevara P éter Ferdinandy Rosalinda Madonna Source Type: research
Antineoplastic drugs inducing cardiac and vascular toxicity - An update
Vascul Pharmacol. 2023 Sep 5:107223. doi: 10.1016/j.vph.2023.107223. Online ahead of print.ABSTRACTWith the improvement in cancer prognosis due to advances in antitumor therapeutic protocols and new targeted and immunotherapies, we are witnessing a growing increase in survival, however, at the same timeincrease in morbidity among cancer survivors as a consequences of the increased cardiovascular adverse effects of antineoplastic drugs. Common cardiovascular complications of antineoplastic therapies may include cardiac complications such as arrhythmias, myocardial ischemia, left ventricular dysfunction culminating in heart ...
Source: Vascular Pharmacology - September 7, 2023 Category: Drugs & Pharmacology Authors: Serena Barachini Sandra Ghelardoni Zolt án V Varga Radwa A Mehanna Maria Magdalena Montt-Guevara P éter Ferdinandy Rosalinda Madonna Source Type: research
Antibody-mediated PCSK9 neutralization worsens outcome after bare-metal stent implantation in mice
CONCLUSION: Antibody-based PCSK9 inhibition promotes in-stent intimal hyperplasia and blunts vascular healing by increasing VSMC migration, while reducing that of EC. This effect is likely mediated, at least in part, by a differential effect on VSMC and EC senescence. The herein-reported data warrant additional investigations concerning the use of PCSK9 inhibitors in patients undergoing PCI with stent implantation.PMID:37659608 | DOI:10.1016/j.vph.2023.107170 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - September 2, 2023 Category: Drugs & Pharmacology Authors: Yustina M Puspitasari Stefano Ministrini Luca Liberale Ana Vukolic Philine Baumann-Zumstein Erik W Holy Fabrizio Montecucco Thomas F L üscher Giovanni G Camici Source Type: research
Antibody-mediated PCSK9 neutralization worsens outcome after bare-metal stent implantation in mice
CONCLUSION: Antibody-based PCSK9 inhibition promotes in-stent intimal hyperplasia and blunts vascular healing by increasing VSMC migration, while reducing that of EC. This effect is likely mediated, at least in part, by a differential effect on VSMC and EC senescence. The herein-reported data warrant additional investigations concerning the use of PCSK9 inhibitors in patients undergoing PCI with stent implantation.PMID:37659608 | DOI:10.1016/j.vph.2023.107170 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - September 2, 2023 Category: Drugs & Pharmacology Authors: Yustina M Puspitasari Stefano Ministrini Luca Liberale Ana Vukolic Philine Baumann-Zumstein Erik W Holy Fabrizio Montecucco Thomas F L üscher Giovanni G Camici Source Type: research
Antibody-mediated PCSK9 neutralization worsens outcome after bare-metal stent implantation in mice
CONCLUSION: Antibody-based PCSK9 inhibition promotes in-stent intimal hyperplasia and blunts vascular healing by increasing VSMC migration, while reducing that of EC. This effect is likely mediated, at least in part, by a differential effect on VSMC and EC senescence. The herein-reported data warrant additional investigations concerning the use of PCSK9 inhibitors in patients undergoing PCI with stent implantation.PMID:37659608 | DOI:10.1016/j.vph.2023.107170 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - September 2, 2023 Category: Drugs & Pharmacology Authors: Yustina M Puspitasari Stefano Ministrini Luca Liberale Ana Vukolic Philine Baumann-Zumstein Erik W Holy Fabrizio Montecucco Thomas F L üscher Giovanni G Camici Source Type: research
Antibody-mediated PCSK9 neutralization worsens outcome after bare-metal stent implantation in mice
CONCLUSION: Antibody-based PCSK9 inhibition promotes in-stent intimal hyperplasia and blunts vascular healing by increasing VSMC migration, while reducing that of EC. This effect is likely mediated, at least in part, by a differential effect on VSMC and EC senescence. The herein-reported data warrant additional investigations concerning the use of PCSK9 inhibitors in patients undergoing PCI with stent implantation.PMID:37659608 | DOI:10.1016/j.vph.2023.107170 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - September 2, 2023 Category: Drugs & Pharmacology Authors: Yustina M Puspitasari Stefano Ministrini Luca Liberale Ana Vukolic Philine Baumann-Zumstein Erik W Holy Fabrizio Montecucco Thomas F L üscher Giovanni G Camici Source Type: research
Antibody-mediated PCSK9 neutralization worsens outcome after bare-metal stent implantation in mice
CONCLUSION: Antibody-based PCSK9 inhibition promotes in-stent intimal hyperplasia and blunts vascular healing by increasing VSMC migration, while reducing that of EC. This effect is likely mediated, at least in part, by a differential effect on VSMC and EC senescence. The herein-reported data warrant additional investigations concerning the use of PCSK9 inhibitors in patients undergoing PCI with stent implantation.PMID:37659608 | DOI:10.1016/j.vph.2023.107170 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - September 2, 2023 Category: Drugs & Pharmacology Authors: Yustina M Puspitasari Stefano Ministrini Luca Liberale Ana Vukolic Philine Baumann-Zumstein Erik W Holy Fabrizio Montecucco Thomas F L üscher Giovanni G Camici Source Type: research
Insights into elastin fiber fragmentation: Mechanisms and treatment of aortic aneurysm in Marfan syndrome
Vascul Pharmacol. 2023 Aug 26:107215. doi: 10.1016/j.vph.2023.107215. Online ahead of print.ABSTRACTMarfan syndrome (MFS) is an autosomal dominant connective tissue disorder caused by fibrillin 1 (FBN1) gene mutations that results in defects in the skeletal, ocular, and cardiovascular systems. Aortic aneurysm is the leading cause of premature mortality in untreated MFS patients. Elastin fiber fragmentation in the aortic vessel wall is a hallmark of MFS-associated aortic aneurysms. FBN1 mutations result in FBN1 fragments that also contribute to elastin fiber fragmentation. Although recent research has advanced our understan...
Source: Vascular Pharmacology - August 28, 2023 Category: Drugs & Pharmacology Authors: Sheilabi Seeburun Shichao Wu Darshi Hemani Lucynda Pham Donghong Ju Youming Xie Priyaranjan Kata Li Li Source Type: research
Insights into elastin fiber fragmentation: Mechanisms and treatment of aortic aneurysm in Marfan syndrome
Vascul Pharmacol. 2023 Aug 26:107215. doi: 10.1016/j.vph.2023.107215. Online ahead of print.ABSTRACTMarfan syndrome (MFS) is an autosomal dominant connective tissue disorder caused by fibrillin 1 (FBN1) gene mutations that results in defects in the skeletal, ocular, and cardiovascular systems. Aortic aneurysm is the leading cause of premature mortality in untreated MFS patients. Elastin fiber fragmentation in the aortic vessel wall is a hallmark of MFS-associated aortic aneurysms. FBN1 mutations result in FBN1 fragments that also contribute to elastin fiber fragmentation. Although recent research has advanced our understan...
Source: Vascular Pharmacology - August 28, 2023 Category: Drugs & Pharmacology Authors: Sheilabi Seeburun Shichao Wu Darshi Hemani Lucynda Pham Donghong Ju Youming Xie Priyaranjan Kata Li Li Source Type: research
Insights into elastin fiber fragmentation: Mechanisms and treatment of aortic aneurysm in Marfan syndrome
Vascul Pharmacol. 2023 Aug 26:107215. doi: 10.1016/j.vph.2023.107215. Online ahead of print.ABSTRACTMarfan syndrome (MFS) is an autosomal dominant connective tissue disorder caused by fibrillin 1 (FBN1) gene mutations that results in defects in the skeletal, ocular, and cardiovascular systems. Aortic aneurysm is the leading cause of premature mortality in untreated MFS patients. Elastin fiber fragmentation in the aortic vessel wall is a hallmark of MFS-associated aortic aneurysms. FBN1 mutations result in FBN1 fragments that also contribute to elastin fiber fragmentation. Although recent research has advanced our understan...
Source: Vascular Pharmacology - August 28, 2023 Category: Drugs & Pharmacology Authors: Sheilabi Seeburun Shichao Wu Darshi Hemani Lucynda Pham Donghong Ju Youming Xie Priyaranjan Kata Li Li Source Type: research
Insights into elastin fiber fragmentation: Mechanisms and treatment of aortic aneurysm in Marfan syndrome
Vascul Pharmacol. 2023 Aug 26:107215. doi: 10.1016/j.vph.2023.107215. Online ahead of print.ABSTRACTMarfan syndrome (MFS) is an autosomal dominant connective tissue disorder caused by fibrillin 1 (FBN1) gene mutations that results in defects in the skeletal, ocular, and cardiovascular systems. Aortic aneurysm is the leading cause of premature mortality in untreated MFS patients. Elastin fiber fragmentation in the aortic vessel wall is a hallmark of MFS-associated aortic aneurysms. FBN1 mutations result in FBN1 fragments that also contribute to elastin fiber fragmentation. Although recent research has advanced our understan...
Source: Vascular Pharmacology - August 28, 2023 Category: Drugs & Pharmacology Authors: Sheilabi Seeburun Shichao Wu Darshi Hemani Lucynda Pham Donghong Ju Youming Xie Priyaranjan Kata Li Li Source Type: research
Circulating soluble IL-6 receptor associates with plaque inflammation but not with atherosclerosis severity and cardiovascular risk
CONCLUSIONS: Our findings show that sIL-6R is a poor marker of CVD risk and associated vascular changes. However, the observation that sIL-6R reflects plaque inflammation highlights the complexity of the role of IL-6 in CVD.PMID:37634789 | DOI:10.1016/j.vph.2023.107214 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - August 27, 2023 Category: Drugs & Pharmacology Authors: Andreas Edsfeldt Isabel Gon çalves Isa Vigren Anja Jovanovi ć Gunnar Engstr öm Angela C Shore Andrea Natali Faisel Khan Jan Nilsson Source Type: research
Circulating soluble IL-6 receptor associates with plaque inflammation but not with atherosclerosis severity and cardiovascular risk
CONCLUSIONS: Our findings show that sIL-6R is a poor marker of CVD risk and associated vascular changes. However, the observation that sIL-6R reflects plaque inflammation highlights the complexity of the role of IL-6 in CVD.PMID:37634789 | DOI:10.1016/j.vph.2023.107214 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - August 27, 2023 Category: Drugs & Pharmacology Authors: Andreas Edsfeldt Isabel Gon çalves Isa Vigren Anja Jovanovi ć Gunnar Engstr öm Angela C Shore Andrea Natali Faisel Khan Jan Nilsson Source Type: research
Amyloid- β: A potential mediator of aging-related vascular pathologies
Vascul Pharmacol. 2023 Aug 23:107213. doi: 10.1016/j.vph.2023.107213. Online ahead of print.ABSTRACTAging is one of the most promising risk factors for vascular diseases, however, the precise mechanisms mediating aging-related pathologies are not fully understood. Amyloid beta (Aβ), a peptide produced by the proteolytic processing of amyloid precursor protein (APP), is known as a key mediator of brain damage involved in the pathogenesis of Alzheimer's disease (AD). Recently, it was found that the accumulation of Aβ in the vascular wall is linked to a range of aging-related vascular pathologies, indicating a potential rol...
Source: Vascular Pharmacology - August 25, 2023 Category: Drugs & Pharmacology Authors: Fazlullah Khan Hongyu Qiu Source Type: research
Amyloid- β: A potential mediator of aging-related vascular pathologies
Vascul Pharmacol. 2023 Aug 23:107213. doi: 10.1016/j.vph.2023.107213. Online ahead of print.ABSTRACTAging is one of the most promising risk factors for vascular diseases, however, the precise mechanisms mediating aging-related pathologies are not fully understood. Amyloid beta (Aβ), a peptide produced by the proteolytic processing of amyloid precursor protein (APP), is known as a key mediator of brain damage involved in the pathogenesis of Alzheimer's disease (AD). Recently, it was found that the accumulation of Aβ in the vascular wall is linked to a range of aging-related vascular pathologies, indicating a potential rol...
Source: Vascular Pharmacology - August 25, 2023 Category: Drugs & Pharmacology Authors: Fazlullah Khan Hongyu Qiu Source Type: research
